|
|
|
|
Plant-based medicines can be harmful
|
|
|
Marketing Authorisations
|
|
|
Metastatic melanoma: a few extra months of life, but many adverse effects
|
|
|
|
|
|
Metastatic melanoma: a me-too of vemurafenib
|
|
|
|
|
|
Multiple sclerosis: too many long-term unknowns
|
|
|
|
|
|
|
An aggressive topical treatment for anogenital warts
|
|
|
|
|
|
Ready to use, but more serious adverse effects than IV trastuzumab
|
|
|
|
|
|
A controversial EU re-evaluation upholds marketing authorisation, unfortunately
|
|
|
|
|
|
An oral solution of phenobarbital with dangerous packaging
|
|
|
|
|
|
More evaluation needed, in both first- and second-line use
|
|
|
Adverse Effects
|
|
|
Hypotension and persistent tachycardia
|
|
|
|
|
|
Stop medication as soon as possible
|
|
|
|
|
|
Miscarriages and major malformations
|
|
|
|
|
|
Unfavourable harm-benefit balance
|
|
|
|
Reviews
|
|
|
Non-randomised comparisons: results similar to those of randomised trials
|
|
|
|
|
|
|
Metformin is the only glucose-lowering drug known to prevent complications of diabetes
|
|
|
|
Outlook
|
|
|
Some advances this year, but many drugs are poorly evaluated, too expensive or more dangerous than useful
|
|
|
|
|
|
Demonstrated impact on prescribing behaviour
|
|
|